BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19189303)

  • 1. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
    Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
    Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.
    Ricciardelli C; Quinn DI; Raymond WA; McCaul K; Sutherland PD; Stricker PD; Grygiel JJ; Sutherland RL; Marshall VR; Tilley WD; Horsfall DJ
    Cancer Res; 1999 May; 59(10):2324-8. PubMed ID: 10344737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.
    Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Tilley WD; Skinner JM; Horsfall DJ
    Clin Cancer Res; 1997 Jun; 3(6):983-92. PubMed ID: 9815775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.
    Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Horsfall DJ
    Clin Cancer Res; 1998 Apr; 4(4):963-71. PubMed ID: 9563891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse.
    Sakko AJ; Butler MS; Byers S; Reinboth BJ; Stahl J; Kench JG; Horvath LG; Sutherland RL; Stricker PD; Henshall SM; Marshall VR; Tilley WD; Horsfall DJ; Ricciardelli C
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2488-97. PubMed ID: 18768520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
    Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].
    Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
    Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
    Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
    Arai T; Fujita K; Fujime M; Irimura T
    Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
    Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P
    Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
    J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.